Adrian Rawcliffe - 12 Aug 2026 Form 4 Insider Report for Wave Life Sciences, Inc. (WVE)

Reporting relationship: Director
Issuer ticker: WVE
Reported as of: 12 Aug 2026
Net transaction value: -$67,183
SEC form: 4
Accepted by SEC: 13 Aug 2026, 21:00:08 UTC
Prior SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Adrian Rawcliffe

Key filing fact

Adrian Rawcliffe filed Form 4 for Wave Life Sciences, Inc. (WVE) on 13 Aug 2026.

Key facts

This page summarizes Adrian Rawcliffe's Form 4 filing for Wave Life Sciences, Inc. (WVE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 21:00.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: -$67,183.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001555851 Primary reporting owner

Rawcliffe Adrian

Relationship: Director
Address: C/O WAVE LIFE SCIENCES, INC.,, 733 CONCORD AVE., CAMBRIDGE
Signature: /s/ Adrian Rawcliffe
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WVE transaction

Common Stock

Sale

Transaction value: $67,183
Shares: -12,700
Change %: -100%
Price: $5.29
Shares after: 0
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

Footnote F2

The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.16 to $5.42 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC remarks

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney